Treatment comparisons

Four names dominate this space and they resolve to two molecules. The confusion is structural rather than accidental: each molecule is sold under one brand licensed for diabetes and another licensed for weight management, and they are covered separately.

Two of the comparisons below work at brand level — one pair licensed for type 2 diabetes, one pair licensed for chronic weight management — and a third works at molecule level, underneath all four brands. Which one you want depends on whether you are choosing between products or trying to understand what is actually in them.

If you are weighing options for weight management, the weight-labeled pair is usually the relevant comparison, even if the diabetes-labeled names are the ones you have heard. They are covered separately by insurers, and that difference decides more outcomes than the pharmacology does.

Peptide comparisons carry a complication the weight-management ones do not: the compounds being compared frequently differ in regulatory status as much as in mechanism, and that gap usually matters more than the pharmacology.

Three of the peptide comparisons below turn on growth hormone signalling, and they split two ways: by receptor, since GHRH analogues and ghrelin-receptor agonists reach the same system by different routes, and by approval, since one of these compounds is an approved medicine for a narrow indication and the others are not approved at all. The fourth compares two unapproved recovery compounds against each other.

In every case, read the regulatory position before the mechanism. A coherent mechanistic story is not evidence, and in this category the gap between those two things is where most of the marketing lives.

• Neutral. We do not rank, and we do not have a preferred option to steer you toward.
• No dosage numbers. Dosing is determined by a licensed provider, and a comparison page is not the place for it.
• No efficacy promises. Where evidence is preclinical or thin, we say so plainly rather than implying more.
• No unsourced prices. Where we cannot cite a published figure with a date, we explain the cost factors instead.
• Every page closes by routing the decision to a licensed provider, because that is genuinely where it belongs.

We have no commercial relationship with any manufacturer, pharmacy or clinic named on these pages, and nothing here is sponsored. Where a page says the evidence is thin, that is the finding rather than a hedge.

The instinct is to read for a verdict. That is usually the least useful thing a comparison can give you, because the deciding factors in this field are rarely properties of the molecule — they are properties of your record and your insurance plan.

A more useful way to read these: work out which of the differences described actually applies to you, and turn that into a question. If one option has an oral form and needles are a real obstacle for you, that is a decision factor. If one carries an additional licensed use that matches something in your history, that is a decision factor. If the difference is a receptor you will never notice, it probably is not.

• Which differences on this page are relevant to my history specifically?
• Which of these does my plan actually cover, and under what conditions?
• What would rule either option out for me?
• What does the prescriber think, once they have seen my record?

Four questions is a better outcome from a comparison page than a winner. The appointment is where the decision gets made, and arriving with the right questions is the thing that changes how it goes.

Comparisons cover the national picture — what a molecule is, what it is licensed for, what drives access. They deliberately do not cover who can prescribe it where you live, because that varies by state and belongs on a page that can be specific about it.

For that layer, the vertical hubs carry state-level coverage: who may prescribe, what telehealth rules apply, and which providers publish a verifiable local presence in the markets we have researched.

• BPC-157 vs TB-500A straight comparison of BPC-157 and TB-500 — their origins, how they are discussed in research, their regulatory status in the US, and why neither is an approved medicine.
• Ipamorelin vs sermorelinIpamorelin and sermorelin compared — what each peptide is, how their mechanisms differ, their very different regulatory status, and why both belong in a prescriber conversation.
• Mounjaro vs OzempicMounjaro and Ozempic compared without hype — the molecules behind each brand, what they are licensed for, how supply and coverage differ, and what to ask a prescriber.
• Semaglutide vs tirzepatideA neutral, plain-English comparison of semaglutide and tirzepatide — how each molecule works, how they are supplied, what drives the cost, and how to decide with a prescriber.
• Tesamorelin vs ipamorelinTesamorelin and ipamorelin compared — an approved GHRH analogue against a ghrelin-receptor agonist, with an honest account of what separates them.
• Tesamorelin vs sermorelinBoth are GHRH analogues, but only one is an approved medicine with a licensed indication. A neutral comparison of tesamorelin and sermorelin and what the difference means.
• Wegovy vs ZepboundWegovy and Zepbound side by side — the molecules, the licensed indications, what drives cost and coverage, and how side effects are discussed with a prescriber.